Yes and this means governments can quickly adapt to new variants by reformulating the vaccine, dumping old stock by "donating" it to developing nations, or dumping it, and buying new stock from big pharma.
Since developing nations will always have far lower vaccination rates than first world countries, the virus will continue to mutate and proliferate outside of America and Europe, ensuring new opportunities for revving the vaccine.
That's a sustainable business model for the first world.